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Table S1a. Baseline characteristics by living situation 
 PWS homea 
N = 23 
Non-PWS 
homeb 
N = 61 
Familyc  
N=28 
Age in years, median [IQR] 26 [21 – 32] 36 [28 – 50] 19 [19 – 22] 
BMI in kg/m2, median [IQR] 27 [22 – 30] 30 [27 – 40] 28 [26 – 36] 
Male gender, n (%) 9 (39%) 30 (49%) 15 (54%) 
Genetic subtype 
Deletion, n (%) 
mUPD, n (%)d 
ICD, n (%) 
Unknown, n (%) 
 
16 (70%) 
6 (26%) 
0 (0%) 
1 (4%) 
 
27 (44%) 
28 (46%) 
1 (2%) 
5 (8%) 
 
18 (64%) 
7 (25%) 
2 (7%) 
1 (4%) 
Growth hormone treatment 
Only during childhood, n (%) 
Only during adulthood, n (%) 
Both, n (%) 
Never, n (%) 
Current growth hormone treatment, n (%) 
 
0 (0%) 
3 (13%) 
12 (52%) 
8 (35%) 
14 (61%) 
 
6 (10%) 
0 (0%) 
9 (15%) 
46 (75%) 
8 (13%) 
 
3 (11%) 
0 (0%) 
19 (68%) 
6 (22%) 
19 (68%) 
Use of hydrocortisone 
Daily, n (%)  
During physical or psychological stress, n (%) 
 
0 (0%) 
16 (70%) 
 
2 (3%) 
13 (21%) 
 
2 (7%) 
17 (61%) 
Scholar level 
Secondary vocational education, n (%) 
Pre-vocational secondary education, n (%) 
Special education, n (%) 
No education, n (%) 
Unknown, n (%) 
 
0 (0%) 
1 (4%) 
16 (70%) 
1 (4%) 
5 (22%) 
 
0 (0%) 
0 (0%) 
46 (75%) 
3 (5%) 
12 (20%) 
 
4 (14%) 
2 (7%) 
19 (68%) 
0 (0%) 
3 (11%) 
Mutism, n (%) 0 (0%) 3 (5%) 0 (0%) 
Relationship status 
In a relationship with sexual intercourse, n (%) 
In a relationship without sexual intercourse, n (%) 
Not in a relationship, n (%) 
Unknown, n (%) 
 
0 (0%) 
5 (22%) 
14 (61%) 
4 (17%) 
 
5 (8%) 
7 (12%) 
40 (66%) 
9 (15%) 
 
2 (7%) 
5 (18%) 
21 (75%) 
0 (0%) 
Abbreviations: body mass index (BMI), interquartile range (IQR). 
a Patients living in a specialized Prader-Willi syndrome home. b Patients living in a non-specialized group home. 
c Patients living with family. d In 11 patients with an mUPD, the parents were not available for genetic testing. 
Therefore, an ICD could not be ruled out with total certainty in these patients.
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Table S1b. Baseline characteristics by genotype 
 Deletion  
N = 64 
mUPDa 
N = 41 
Other  
N = 10 
Age in years, median [IQR] 28 [21 – 36] 32 [21 – 49] 26 [22 – 48] 
BMI in kg/m2, median [IQR] 31 [26 – 38] 29 [25 – 34] 27 [24 – 28] 
Male gender, n (%) 28 (44%) 20 (49%) 8 (80%) 
Growth hormone treatment 
Only during childhood, n (%) 
Only during adulthood, n (%) 
Both, n (%) 
Never, n (%) 
Current growth hormone treatment, n (%) 
 
7 (11%) 
3 (5%) 
20 (31%) 
34 (53%) 
22 (34%) 
 
1 (2%) 
0 (0%) 
16 (39%) 
24 (59%) 
15 (37%) 
 
2 (20%) 
0 (0%) 
4 (40%) 
4 (40%) 
4 (40%) 
Use of hydrocortisone 
Daily, n (%)  
During physical or psychological stress, n (%) 
 
3 (5%) 
24 (38%) 
 
1 (2%) 
18 (44%) 
 
0 (0%) 
5 (50%) 
Living situation 
With family, n (%) 
In a specialized Prader-Willi group home, n (%) 
In a non-specialized group home, n (%) 
Assisted living, n (%) 
 
18 (28%) 
16 (25%) 
27 (42%) 
3 (5%) 
 
7 (17%) 
6 (15%) 
28 (68%) 
0 (0%) 
 
3 (30%) 
1 (10%) 
6 (60%) 
0 (0%) 
Scholar level 
Secondary vocational education, n (%) 
Pre-vocational secondary education, n (%) 
Special education, n (%) 
No education, n (%) 
Unknown, n (%) 
 
6 (9%) 
1 (2%) 
46 (72%) 
0 (0%) 
11 (17%) 
 
0 (0%) 
1 (2%) 
31 (76%) 
4 (10%) 
5 (12%) 
 
0 (0%) 
1 (10%) 
5 (50%) 
0 (0%) 
4 (40%) 
Mutism, n (%) 0 (0%) 2 (5%) 1 (10%) 
Relationship status 
In a relationship with sexual intercourse, n (%) 
In a relationship without sexual intercourse, n (%) 
Not in a relationship, n (%) 
Unknown, n (%) 
 
6 (9%) 
15 (23%) 
41 (64%) 
1 (2%) 
 
2 (5%) 
2 (5%) 
30 (73%) 
7 (17%) 
 
0 (0%) 
1 (10%) 
5 (50%) 
4 (40%) 
Abbreviations: body mass index (BMI), imprinting center defect (ICD), interquartile range (IQR), maternal 
uniparental disomy (mUPD). 
a In 11 patients with an mUPD, the parents were not available for genetic testing. Therefore, an ICD could not 
be ruled out with total certainty in these patients. 
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Table S2a. Health problems before and after our systematic screening by living situation 
 PWS homea  
N = 23 
Non-PWS homeb 
N = 61 
Familyc  
N=28 
P-value 
Before  After Missing Before After Missing Before After Missing 
Hypogonadism 
    Male (n=54) 
    Female (n=58)d 
 
5 (56%) 
10 (100%) 
 
9 (100%) 
10 (100%) 
 
0 
4 
 
10 (36%) 
10 (43%) 
 
28 (100%) 
20 (87%) 
 
2 
8 
 
10 (67%) 
6 (60%) 
 
15 (100%) 
10 (100%) 
 
0 
3 
 
NA 
0.2 
Hypothyroidism 3 (13%) 4 (17%) 0 11 (18%) 12 (20%) 0 3 (11%) 3 (11%) 0 0.6 
Type 2 diabetes 
mellitus 
2 (9%) 2 (9%) 0 9 (15%) 13 (22%) 2 1 (4%) 3 (11%) 0 0.2 
Hypertension 0 (0%) 0 (0%) 1 11 (19%) 17 (29%) 2 1 (4%) 2 (7%) 0 0.002 
Hypercholesterolemia 2 (9%) 4 (17%) 0 9 (15%) 15 (25%) 2 2 (7%) 2 (7%) 0 0.1 
Scoliosis 15 (65%) 18 (78%) 0 31 (53%) 44 (76%) 3 14 (50%) 19 (68%) 0 0.6 
Vitamin D deficiency 11 (69%) 14 (88%) 7 7 (27%) 22 (85%) 35 8 (32%) 16 (64%) 3  
Data are presented as n (%). 
All P-values show the difference in both groups after screening. 
a Patients living in a specialized Prader-Willi syndrome group home. b Patients living in a non-specialized group home. c Patients living with family. d (Caregivers of) 15 female 
patients did not recall whether they had had a normal menstrual cycle before the start of oral contraceptives or before reaching menopausal age.
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Table S2b. Health problems after our systematic screening by genotype 
 Deletion 
N = 64 
Missing mUPD 
N = 41 
Missing P-value 
Hypogonadism 
    Male (n=48) 
    Female (n=57)a 
 
27 (100%) 
25 (93%) 
 
1 
9 
 
19 (100%) 
14 (93%) 
 
1 
6 
 
NA 
0.9 
Hypothyroidism 11 (17%) 0 7 (17%) 0 0.99 
Type 2 diabetes 
mellitus 
8 (13%) 0 10 (24%) 2 0.1 
Hypertension 9 (15%) 0 8 (20%) 2 0.5 
Hypercholesterolemia 11 (17%) 1 8 (20%) 1 0.7 
Scoliosis 51 (81%) 2 23 (59%) 1 0.02 
Vitamin D deficiency 33 (80%) 16 19 (76%) 23  
Data are presented as n (%). 
Abbreviations: maternal uniparental disomy (mUPD). 
a (Caregivers of) 15 female patients did not recall whether they had had a normal menstrual cycle before the start of 
oral contraceptives or before reaching menopausal age. 
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Table S2c. Health problems after our systematic screening by BMI 
 BMI <25 
kg/m2 
N = 24 
Missing BMI 25-30 
kg/m2 
N = 43 
Missing BMI >30 
kg/m2 
N = 48 
Missing P-value 
Hypogonadism 
    Male (n=56) 
    Female (n=59)a 
 
11 (100%) 
6 (100%) 
 
1 
6 
 
27 (100%) 
12 (92%) 
 
1 
2 
 
16 (100%) 
22 (92%) 
 
0 
8 
 
NA 
0.9 
Hypothyroidism 5 (21%) 0 7 (16%) 0 7 (15%) 0 0.5 
Type 2 diabetes 
mellitus 
2 (8%) 0 7 (17%) 1 10 (21%) 1 0.2 
Hypertension 3 (13%) 0 6 (15%) 2 11 (23%) 1 0.4 
Hypercholesterolemia 4 (17%) 0 4 (10%) 1 14 (30%) 1 0.01 
Scoliosis 12 (79%) 0 30 (71%) 1 34 (74%) 2 0.3 
Vitamin D deficiency 12 (75%) 8 20 (77%) 17 22 (81%) 21  
Data are presented as n (%). 
Abbreviations: body mass index (BMI). 
a (Caregivers of) 16 female patients did not recall whether they had had a normal menstrual cycle before the start of 
oral contraceptives or before reaching menopausal age. 
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Table S2d. Health problems after our systematic screening by age 
 Age < 25 
year 
N = 43 
Missing Age 25-30 
year 
N = 21 
Missing Age > 30 
year 
N = 51 
Missing P-value 
Hypogonadism 
    Male (n=59) 
    Female (n=56)a 
 
20 (100%) 
18 (100%) 
 
0 
5 
 
7 (100%) 
9 (90%) 
 
1 
3 
 
27 (100%) 
13 (87%) 
 
1 
8 
 
NA 
0.2 
Hypothyroidism 10 (23%) 0 5 (24%) 0 4 (8%) 0 0.2 
Type 2 diabetes 
mellitus 
2 (5%) 0 2 (10%) 0 15 (31%) 2 <0.001 
Hypertension 3 (7%) 1 1 (5%) 2 16 (31%) 0 <0.001 
Hypercholesterolemia 3 (7%) 0 2 (10%) 0 17 (35%) 2 0.002 
Scoliosis 30 (70%) 0 19 (90%) 0 34 (71%) 3 0.9 
Vitamin D deficiency 27 (69%) 4 10 (91%) 10 17 (89%) 32  
Data are presented as n (%). 
a (Caregivers of) 16 female patients did not recall whether they had had a normal menstrual cycle before the start of 
oral contraceptives or before reaching menopausal age. 
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Table S2e. Health problems after our systematic screening by gender 
 Male 
N = 56 
Missing Female 
N = 59 
Missing P-value 
Hypothyroidism 5 (9%) 0 14 (24%) 0 0.03 
Type 2 diabetes 
mellitus 
13 (24%) 1 6 (10%) 1 0.06 
Hypertension 9 (17%) 2 11 (19%) 1 0.8 
Hypercholesterolemia 10 (18%) 1 12 (21%) 1 0.7 
Scoliosis 42 (76%) 1 41 (72%) 2 0.6 
Vitamin D deficiency 25 (83%) 26 29 (74%) 20  
Data are presented as n (%). 
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Table S3. Lifestyle and behaviour 
Missing 
Total 
N = 115 
PWS 
homea 
N = 23 
Non-PWS 
homeb 
N = 61 
Familyc 
N = 28 
Physical exercise <30 
minutes a day 
0 25 (22%) 0 (0%) 18 (30%) 7 (25%) 
No dietitian 0 42 (37%) 3 (13%) 16 (26%) 20 (71%) 
Increasing weight 0 44 (38%) 5 (22%) 15 (25%) 15 (54%) 
Problems regarding living, 
work, daytime activities or 
care takers 
24 41 (45%) 5 (22%) 25 (52%) 11 (39%) 
Difficulties dealing with 
behavioural problems 
26 42 (47%) 4 (17%) 28 (46%) 9 (32%) 
Data are presented as n (%). 
a Patients living in a specialized Prader-Willi syndrome group home. b Patients living in a non-specialized group home. c 
Patients living with family. 
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Table S4. Total physical complaints 
 Missing 
Total 
N = 115 
Skin picking 21 53 (56%) 
Food seeking behaviour 23 42 (46%) 
Daytime sleepiness 19 41 (43%) 
Temper tantrums 20 40 (42%) 
Leg edema 20 32 (34%) 
Snoring 19 32 (33%) 
Foot complaints 20 30 (32%) 
Nycturia 21 28 (30%) 
Fatigue 22 23 (25%) 
Feeling cold 22 22 (24%) 
Constipation 18 21 (22%) 
Thirst 26 19 (21%) 
Visual complaints 23 18 (20%) 
Stomach ache 20 15 (16%) 
Diarrhea  19 15 (16%) 
Backache 22 15 (16%) 
Pyrosis / ructus 22 13 (14%) 
Pica (eating nonfood items) 23 10 (11%) 
Sexual problems 22 9 (10%) 
Difficulty sleeping 22 9 (10%) 
Urinary incontinence 20 9 (9%) 
Fecal incontinence 21 6 (6%) 
Chestpain 24 4 (4%) 
Bone fractures 19 3 (3%) 
Orthopnea 25 3 (3%) 
Vomiting 20 0 (0%) 
Complaints are scored as present when the caregivers indicated a score of 3 or higher on a 5-point Likertscale. 
Data are presented as n (%). 
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Table S5. Liver panel, kidney function, hematopoiesis and electrolyte values of 115 adults with PWS  
 
 
N 
Reference 
range Median [IQR] Min-max 
Patients below 
LLN, n (%) 
Patients above 
ULN, n (%) 
ASAT (U/L) 
Male 
Female 
54 
55 
<35 
<31 
21 [18 – 25] 
20 [17 – 25] 
11 – 82 
11 – 52 
NAa 
2 (4%) 
4 (7%) 
ALAT (U/L) 
Male 
Female 
54 
56 
<45 
<34 
21 [16 – 28] 
20 [15 – 23] 
10 – 149 
9 – 76 
NAa 
5 (9%) 
5 (9%) 
ALP (U/L) 
Male 
Female 
52 
52 
<115 
<98 
86 [65 – 107] 
77 [60 – 96] 
17 – 180 
25 – 211 
NAa 
8 (15%) 
11 (21%) 
GGT (U/L) 
Male 
Female 
54 
53 
<55 
<38 
18 [15 – 27] 
19 [13 – 31] 
9 – 165 
9 – 85 
NAa 
2 (4%) 
9 (17%) 
Total bilirubin (µmol/L) 
Male 
Female 
48 
49 
<17 
<17 
5.0 [4.0 – 8.0] 
4.0 [3.5 – 6.0] 
3.0 – 25 
3.0 – 18 
NAa 
2 (4%) 
1 (2%) 
LDH (U/L) 
Male 
Female 
50 
50 
<248 
<247 
200 [170 – 223] 
178 [166 – 213] 
118 – 270 
132 – 299 
NAa 
4 (8%) 
5 (10%) 
Urea (mmol/L)  107 2.5 – 7.5 4.4 [3.7 – 5.0] 1.8 – 10.6 2 (2%) 3 (3%) 
Creatinine (µmol/L) 
Male 
Female 
56 
59 
65 – 115 
55 – 90  
61 [51 – 72] 
56 [49 – 65] 
40 – 109 
31 – 89 
35 (63%) 
28 (47%) 
0 (0%) 
0 (0%) 
Hemoglobin (mmol/L) 
Male 
Female 
55 
53 
8.6 – 10.5  
7.5 – 9.5 
8.9 [8.4 – 9.4] 
8.2 [8.0 – 9.0] 
7.3 – 10.1 
6.8 – 9.7 
17 (31%) 
1 (2%) 
0 (0%) 
1 (2%) 
MCV (fL)  111 80 – 100 90 [87 – 92] 78 – 101 1 (1%) 1 (1%) 
Sodium (mmol/L)  111 136 – 145 140 [138 – 142] 130 – 145 8 (7%) 0 (0%) 
Potassium (mmol/L)  111 3.5 – 5.1 4.3 [4.1 – 4.5] 3.4 – 5.4 1 (1%) 2 (2%) 
Calcium (mmol/L)  107 2.20 – 2.65 2.4 [2.3 – 2.5] 1.2 – 4.0 3 (3%) 2 (2%) 
Albumin (g/L)  105 35 – 50 45 [42 – 48] 30 – 53 3 (3%) 5 (5%) 
Abbreviations: upper limit of normal (ULN), lower limit opf normal (LLN), alanine transaminase (ALAT), alkaline 
phosphatase (ALP), aspartate transaminase (ASAT), gamma glutamyl transpeptidase (GGT), interquartile range (IQR), 
lactate dehydrogenase (LDH), mean corpuscular volume (MCV). a Unknown, because LLN not defined. 
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Figure S1. Sleep apnea: clinical data and poly(somno)graphy results 
 
Abbreviations: CSA (central sleep apnea), PG (polygraphy), PSG (polysomnography), OSA (obstructive sleep apnea). 
Legens: Grey arrows and squares represent patients in which polygraphy was not performed. Double lined arrows 
and squares represent patients that were diagnosed with sleep apnea. Bold arrows and squares represent patients 
in which sleep apnea was excluded.  
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Figure S2. Osteopenia and osteoporosis 
 
Abbreviations: BMD (bone mineral density), DEXA (dual energy X-ray absorptiometry). 
Legens: The grey arrow and square represent patients in which DEXA was not performed. Double lined arrows and 
squares represent patients that were diagnosed with osteoporosis or osteopenia. The bold arrow and square 
represent patients in which osteoporosis and osteopenia were excluded.
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Figure S3. Vitamin D deficiency 
 
Legens: The grey arrow and square represent patients that received vitamin D supplementation before screening 
for unknown reasons. Double tined arrows and squares represent patients that were diagnosed with vitamin D 
deficiency. The bold arrow and square represent patients in which vitamin D deficiency was excluded. 
